抗凝药选择对癌症相关静脉血栓栓塞症住院出血风险的影响
该回顾性研究基于美国大型行政数据库,纳入2011至2015年诊断的26894例癌症相关静脉血栓栓塞症(CA-VTE)患者,随访住院严重出血。随访27281人年(中位0.6年)发生1204例出血事件,出血率为每患者年4.4%。与华法林相比,直接口服抗凝药(DOACs)和低分子肝素(LMWH)的出血风险相似(HR分别为0.88和0.98);与LMWH相比,DOACs无差异(HR 0.86)。DOACs的出血风险因癌症类型而异,上消化道癌较高,前列腺癌和血液系统肿瘤较低。
要点
- CA-VTE患者中,DOACs与华法林相比住院出血风险相似(HR 0.88,95%CI 0.69-1.11)。
- DOACs与LMWH相比出血风险无差异(HR 0.86,95%CI 0.66-1.12)。
- DOACs出血风险因癌症类型而异,上消化道癌较高,前列腺癌和血液系统肿瘤较低。
核心结论
- 在CA-VTE患者中,DOACs与华法林和LMWH的出血风险相似。
- 这些发现提示癌症患者出血风险与抗凝药选择之间存在复杂的关联。
研究设计与样本
- 回顾性研究,使用大型行政数据库,纳入2011至2015年诊断的CA-VTE患者26894例,随访住院严重出血。
- 采用Cox模型评估出血风险,调整年龄、性别、高维倾向评分和衰弱。
主要发现
- 随访27281人年(中位0.6年),发生1204例出血事件,出血率为每患者年4.4%。
- 出血率因癌症类型而异,上消化道癌最高(8.6%),乳腺癌最低(2.9%)。
- 与华法林相比,DOACs的出血HR为0.88(95%CI 0.69-1.11),LMWH的出血HR为0.98(95%CI 0.85-1.13)。
- 与LMWH相比,DOACs的出血HR为0.86(95%CI 0.66-1.12)。
- DOACs的出血风险因癌症类型存在异质性,上消化道癌出血风险较高,前列腺癌和血液系统肿瘤出血风险较低。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Bleeding risk by anticoagulant choice for cancer-associated venous thrombosis (CA-VTE) is unknown. 26 894 people with CA-VTE were followed for bleeding in a claims database in the United States. Hospitalized bleeding risk was similar with direct acting oral anticoagulants vs. warfarin. Relative hospitalized bleeding risk varied by cancer type and anticoagulant choice. SUMMARY: Background Direct acting oral anticoagulants (DOACs) are associated with less bleeding than traditional venous thromboembolism (VTE) treatments in the general population but are little studied in cancer-associated VTE (CA-VTE). Objective To determine whether different anticoagulation strategies for CA-VTE have different hospitalized bleeding rates. Patients/Methods We conducted a retrospective study of patients with CA-VTE, diagnosed between 2011 and 2015, in a large administrative database. Using validated algorithms, we identified 26 894 CA-VTE patients treated with anticoagulants and followed them for hospitalized severe bleeding. Cox models were used to assess bleeding risk, adjusted for age, sex, high dimensional propensity score and frailty. Results Over 27 281 person-years of follow-up (median 0.6 years), 1204 bleeding events occurred, for a bleeding rate of 4.4% per patient-year. Bleeding rates varied by cancer type, with the highest rate for upper gastrointestinal cancers (8.6%) and the lowest for breast cancer (2.9%). In Cox models (hazard ratio [HR]; 95% confidence interval [CI]), compared with warfarin, DOACS and low-molecular-weight heparin (LMWH) had similar hazards of bleeding (HR, 0.88; 95% CI, 0.69-1.11 and 0.98; 0.85-1.13). Compared with LMWH, there was no difference in hazard of bleeding with DOACs (0.86; 0.66-1.12). There was heterogeneity in bleeding risk with DOACs by cancer type, with a higher risk of bleeding in upper gastrointestinal cancers and lower risk of bleeding in prostate cancer and hematologic cancers. Conclusions In this practice-based sample of CA-VTE patients, DOACs were associated with similar bleeding risks to warfarin and LMWH. These findings suggest a complex association of bleeding risk with anticoagulant choice in cancer patients.
引用
- Zakai NA, Walker RF, MacLehose RF, et al. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. J Thromb Haemost. 2018. PMID: 30240508. doi:10.1111/jth.14303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。